Roche reports positive data for new combination kidney cancer therapy

Roche has announced new clinical trial data showing the effectiveness of a promising new kidney cancer regimen.

Results from the phase III IMmotion151 study showed that a combination of Tecentriq and Avastin delivered significant benefits as a first-line treatment for advanced or metastatic renal cell carcinoma.

The study met its co-primary endpoint of investigator-assessed progression-free survival in people whose disease expressed the PD-L1 protein, with those receiving the Roche-developed therapy experiencing a 26 percent lower risk of their disease worsening or death, compared to people treated with another therapy.

Dr Sandra Horning, chief medical officer and head of global product development at Roche, said: "This is the second positive phase III study that includes Tecentriq and Avastin as part of a treatment regimen, providing further evidence to support the potential of this unique combination."

Roche plans to discuss the positive findings from the IMmotion151 study with global health authorities, including the US Food and Drug Administration and the European Medicines Agency, in the coming months.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.